Interview, Fireside Chat
Can Psychedelics Improve Mental Health? With C. Angermayer & Uma Thurman | Global Conference 2021
- Uma Thurman anticipates a 30-minute conversation followed by a Q&A session.
- Christian Angermeyer forecasts a sharp and sustained rise in global mental health issues driven by COVID-19 lockdowns, media fear, destigmatization, and technology's harmful effects on the brain, affecting all ages including loneliness among the young and elderly.
- Angermeyer projects his company's drug candidates will advance from Phase 2 to Phase 3 trials in the coming years, with multiple approvals expected in Europe and the US within several years, contingent on FDA success.
- He expects that following FDA medical approval, drugs will be automatically reclassified as therapeutic, with specific guidance sought for a new, softer ketamine version potentially approved for limited at-home use.
- The outlook includes a business strategy relying on the growing global patient population, with potential revenue streams from curative treatments necessitating potential annual sessions to prevent relapse.
- Angermeyer identifies 16+ development applications including depression, anxiety, addiction, cluster headaches, and migraines, with future treatment definitions expected to expand over the next decade to address societal issues like the inability to adapt to technology.
- Regulatory and societal changes are anticipated where therapists retain full authority to determine patient eligibility based on root causes, leading to widespread acceptance and "positively viral" adoption as patients advocate for the treatments.
- A long-term prediction suggests that while politicians may privately use psychedelics now, public discourse among world leaders is expected within a timeframe exceeding 20 years, though near-term political applications for reconciliation are possible.
- Scientific advancements in brain understanding over the last five to seven years support the expectation that the Default Mode Network will be reduced during use, fostering months of continued brain growth, restored creativity, and an effect resembling a "younger brain."
- Risks include the potential for psychedelics to cause mental illness if administered improperly, leading to a firm stance against over-the-counter sales in favor of doctor-administered medical treatments with healing intentions.
- Angermeyer plans to announce "big news" regarding a supporting nonprofit initiative in the coming weeks.